Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Dr. Barbara Schmidtman shares why taking time off this spring or summer is important for leaders and their teams' self-care and job satisfaction.
A C C C ’ S C A L L T O A C T I O N : D E L I V E R Y O F P S Y C H O S O C I A L C A R E I N O N C O L O G Y S U M M I T ASSOCIATION OF COMMUNITY CANCER CENTERS Program Background The burden of cancer is far greater than the diagnosis of a single tumor. When patients receive a cancer diagnosis, every facet of their life—physical, mental, emotional, social, …
New Molecular Entities • None Changes in Labeled Indications • Polivy® (polatuzumb vedotin) --Genentech’s antibody-drug conjugate (ADC), which came to market with an accelerated approval for use (after at least two prior therapies) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), has now gained FDA’s approval for treating newly diagnosed patients. The …
PowerPoint Presentation May 11, 2023 TxSCO Update Overview: Notable Updates 2 Federal • PHE expires today, May 11th • In-office dispensers and mail order drugs • Telehealth • Medicaid enrollment drop • USPSTF Recommends Biennial Mammograms at age 40 • ACS CAN Report: Cancer deaths by congressional district • EOM: the latest State • Update …
ACCCBuzz spoke with Erika Siegrist at Luminis Health Research Institute to learn more about how technology has helped expand patient access to cancer clinical trials.
New Molecular Entities • None Changes in Labeled Indications • Polivy® (polatuzumb vedotin) --Genentech’s antibody-drug conjugate (ADC), which came to market with an accelerated approval for use (after at least two prior therapies) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), has now gained FDA’s approval for treating newly diagnosed patients. The …
In 2022, ACCC conducted a survey to measure patient, caregiver, and provider perceptions and adoption of messaging tools, electronic questionnaires, and connected devices used to track and monitor symptoms during cancer treatment.
Scan the QR code with your smartphone or visit the link below to explore this program. The ASCO Direct™ Highlights program reviews practice-changing data and other “hot topics” discussed at the premier clinical oncology conference in North America, including information about hematologic malignancies and thoracic, breast, gastrointestinal, genitourinary, gynecologic, and dermatologic …
1 Mazyar Shadman, MD MPH Associate Professor Fred Hutch Cancer Center and University of Washington Seattle, WA Immunotherapy for Lymphoma 2Fred Hutchinson Cancer Center Research funding from: Mustang Bio, BMS, Pharmacyclics, Genentech, AbbVie,TG Therapeutics, BeiGene, AstraZeneca, Genmab, MorphoSys/Incyte, Vincerx Consulting for: AbbVie, Genentech, AstraZeneca, …
Fred Hutchinson Cancer Center Community Cancer Care Report Updates Hutchinson Institute for Cancer Outcomes Research (HICOR) Veena Shankaran MD, MS (Co-Director) Scott Ramsey MD, PhD (Director) Fred Hutchinson Cancer Center HICOR Mission Improve the effectiveness of cancer prevention, early detection and treatment services in ways that reduce the economic and human burden …
New Molecular Entities • None Changes in Labeled Indications • Polivy® (polatuzumb vedotin) --Genentech’s antibody-drug conjugate (ADC), which came to market with an accelerated approval for use (after at least two prior therapies) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), has now gained FDA’s approval for treating newly diagnosed patients. The …
May 20, 2023
In this workshop, provided by the France Foundation, interactive formats will allow the multidisciplinary care team to continuously assess knowledge gaps.
Developing a Health Literacy and Clear Communications e-Course 1 ASSOCIATION OF COMMUNITY CANCER CENTERS accc-cancer.org Who Took Our Survey? Top Reported Benefits of Using Technology to Share Symptoms with the Healthcare Team Adoption of RPM in Cancer Care RPM adoption is building momentum; most cancer programs and practices reported at least early planning for this …
ACCC is announcing the release of a new tool intended to support the education of multidisciplinary care team members and adoption of technological and operational advancements.
New Molecular Entities • None Changes in Labeled Indications • Polivy® (polatuzumb vedotin) --Genentech’s antibody-drug conjugate (ADC), which came to market with an accelerated approval for use (after at least two prior therapies) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), has now gained FDA’s approval for treating newly diagnosed patients. The …
WSMOS 2023 SPRING CONFERENCE MAY 19, 2023 SEATTLE, WA Attendee List Name Title Organization Cathy Simpson Account Executive AbbVie Inc. Dylan Barth Medical Science Liaison AbbVie Inc. Jules Holland Account Executive AbbVie Inc. Vincent Vidaurri Account Executive AbbVie Inc. Brandon Cogo Account Executive Amgen Oncology Jason Robison Account Executive Amgen …
In the rapidly changing precision medicine landscape, community cancer programs seeking to incorporate newly actionable biomarkers face multiple barriers due to insufficient biomarker testing processes, expertise, and finan- cial and operational resources. To address this widening gap, ACCC’s education program, Evolving Biomarkers in Non-Small Cell Lung Cancer (NSCLC), examines these challenges …
Telehealth can improve the experience of patients with cancer by facilitating access and reducing cost.
May 18, 2023
Cedarbrook Lodge 18525 36th Avenue South, Seattle, WA 98188 Please check back for more information including agenda, registration — coming soon.